Pediatric Polypharmacy

Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study

“…Our results are consistent with several published investigations conducted in pediatric patients that also show polypharmacy to be an important factor that predisposes to ADRs [ 38 ]. Polypharmacy as a risk factor for ADRs is well characterized in adults and older subjects [ 40 ] and descriptive data are also available in children [ 41 ], but the risk of serious ADRs had not been addressed previously.…”

Biomaterial-Driven Immunomodulation: Cell Biology-Based Strategies to Mitigate Severe Inflammation and Sepsis

“…A polypharmacological strategy has the potential to address the redundant molecular, cellular, and tissue functions during inflammation but anti-inflammatory and anti-coagulants are neither innocuous nor without potential adverse effects in combination or alone. Of particular note is that morbidity and mortality associated with sepsis and septic shock tends to be most severe within the geriatric and pediatric population, two groups where polypharmacy can be especially deleterious in combination with existing comorbidities or developmental concerns (145)(146)(147)(148)(149). Given these concerns with a multi-drug approach, other strategies that can work with multimodal mechanisms of action and minimize adverse effects are ideal and ongoing research with biomaterials serves as an exciting area to deliver on some of these strategies.…”

Polypharmacy in Pediatrics: Modern Conditions

“…Несмотря на имеющуюся неопределенность в безопасности ЛП у детей, потребление ЛП в педиатрической практике растет. Полипрагмазия является «нормой» для госпитализированных младенцев и детей [7]. В 2002 г. в США был принят Закон о наилучших ЛП для детей (Best Pharmaceuticals for Children Act), основной целью которого является уменьшение количества врачебных ошибок, в том числе связанных с одновременным назначением большого числа ЛП госпитализированным детям [8].…”